Prostate Cell News Volume 3.19 | May 25 2012

Exome Sequencing Identifies Recurrent SPOP, FOXA1 and MED12 Mutations in Prostate Cancer
Researchers sequenced the exomes of 112 prostate tumor and normal tissue pairs and identified new recurrent mutations in multiple genes, including MED12 and FOXA1. [Nat Genet] Abstract | Press Release

LABORATORY RESEARCH

Epigenetic Markers of Prostate Cancer in Plasma Circulating DNA
Researchers investigated circulating DNA  modifications in prostate cancer patients with locally-confined disease, in patients with benign prostate hyperplasias, and in men without any known prostate disease. [Hum Mol Genet] Abstract

BTG2 Loss and MicroRNA-21 Upregulation Contribute to Prostate Cell Transformation by Inducing Luminal Markers Expression and Epithelial-Mesenchymal Transition
Scientists investigated whether downregulation of the basal protein B-cell translocation gene 2 (BTG2) is implicated in prostate cancer transformation and progression. [Oncogene] Abstract

Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy
Investigators characterized the importance of cellular Fas-associated death domain-like interleukin 1Β-converting enzyme inhibitory protein (c-FLIP) in modulating the response of prostate cancer cells to androgen receptor-targeted therapy. [Clin Cancer Res] Abstract

Spondin-2 (SPON2), a More Prostate-Cancer-Specific Diagnostic Biomarker
Scientists found that the serum SPON2 level was elevated in prostate cancer patients, showing sensitivity and specificity suitable for diagnostic use. [PLoS One] Full Article

Gene Expression Profiles of Prostate Cancer Stem Cells Isolated by Aldehyde Dehydrogenase Activity Assay
Researchers evaluated the aldehyde dehydrogenase activity of the human prostate cancer cell line 22Rv1 with the ALDEFLUOR® assay and determined its potency as prostate cancer stem-like/cancer initiating cells. [J Urol] Abstract

Methyltransferase Inhibitor Adenosine Dialdehyde Suppresses Androgen Receptor Expression and Prostate Cancer Growth
Investigators examined the effects of the methyltransferase inhibitor adenosine dialdehyde on the methylation state of histone H3 lysine 9 and androgen receptor gene expression as well as its possible usefulness for prostate cancer. [J Urol] Abstract

Synergistic Activity of the mTOR Inhibitor Ridaforolimus and the Antiandrogen Bicalutamide in Prostate Cancer Models
Investigators used the potent inhibitor ridaforolimus to target mTOR signaling alone and in combination with androgen receptor blockade by bicalutamide to examine the effect of abrogating these signaling pathways. [Int J Oncol] Abstract | Full Article 

Metformin Enhances the Antiproliferative and Apoptotic Effect of Bicalutamide in Prostate Cancer
Researchers assessed the potential additive benefit of combining bicalutamide antiandrogen therapy with metformin, in vitro and in vivo. [Prostate Cancer Prostatic Dis] Abstract

CLINICAL RESEARCH

Clinical Outcome of Patients Treated with 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on RTOG 9406
Investigators report of clinical cancer control outcomes on radiation therapy oncology group (RTOG) 9406, a 3D-CRT dose escalation trial for localized adenocarcinoma of the prostate. [Int J Radiat Oncol] Abstract

Implanted Dosimeters Identify Radiation Overdoses during IMRT for Prostate Cancer
Scientists report their initial clinical experience using implantable dosimeters to quantify and adjust the dose received during intensity-modulated radiotherapy (IMRT). [Int J Radiat Oncol] Abstract

600 Patients Recruited in Active Biotech’s and Ipsen’s Tasquinimod Clinical Phase III Study
Active Biotech and Ipsen announced that recruitment to the global, pivotal, randomized, double-blind, placebo-controlled phase III study of tasquinimod in patients with metastatic castrate-resistant prostate cancer has reached an inclusion of 600 patients, half of the planned accrual. [Active Biotech AB] Press Release

MDxHealth’s ConfirmMDx™ for Prostate Cancer Test Helps to Identify Men Able to Avoid Repeat Biopsies
MDxHealth SA announced it has presented data demonstrating that its epigenetic ConfirmMDx™ for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy. [MDxHealth SA] Press Release

Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated with Chemotherapy
Medivation, Inc. and Astellas Pharma Inc. announced that Medivation has submitted a New Drug Application to the U.S. Food and Drug Administration for enzalutamide. [Medivation, Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Stem Cells USA & Regenerative Medicine Congress
September 20-21, 2012 
Boston, United States 

Visit our events page to see a complete list of events in the prostate cell community.

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Associate Research Scientist (Columbia University Medical Center)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Fellow – Prostate Research (Baylor College of Medicine)

 Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.